Evidence map›Paper›PMID 40882982›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2025

Lpar5 regulates the CD8 T-cell response to persistent virus infection by altering exhaustion programming, survival, and NK receptor expression.

Marc A D'Antonio, Brian C Ware, James E DiLisio, Mary Jessamine Michaels, Jacqueline A Turner, Lauren M Habenicht, Bennett J Davenport, Thomas E Morrison, Roberta Pelanda, Laurent Gapin and 1 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. CD8Cancer cell international · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marc A D'AntonioDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Brian C WareDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
James E DiLisioDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Mary Jessamine MichaelsDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Jacqueline A TurnerDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Lauren M HabenichtOffice of Laboratory Animal Resources and Department of Pathology, Anschutz Medical Campus, Aurora, CO, United States.
Bennett J DavenportDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Thomas E MorrisonDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Roberta PelandaDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Laurent GapinDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Raul M TorresDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.ORCID 0000-0002-5969-5957

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI PETER J DEMPSEY · 2020 to 2026
$10.8M
TRAINING PROGRAM IN IMMUNOLOGYT32AI007405 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Laurel L Lenz, Raul Martin Torres · 1991 to 2026
$10.5M
Lysophosphatidic Acid Regulation of CD8 T cell activation and functionR01AI143261 · NIAID · UNIVERSITY OF COLORADO DENVER · PI TORRES, RAUL MARTIN · 2020 to 2024
$2.6M
Testing Modified Approaches to Informed ConsentR21AI074005 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KASS, NANCY E · 2008 to 2010
$582k
Induction of tolerance to a Hybrid Insulin Peptide and the impact on autoreactive T cell fate and function in autoimmune diabetic islet transplantF31AI181452 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DILISIO, JAMES E · 2024 to 2025
$80k
National Institute of Allergy and Infectious Diseases T32NCI NIH HHS P30 CA046934NIAID NIH HHS F31 AI181452NIAID NIH HHS R01 AI143261NIAID NIH HHS R21 AI074005NIAID NIH HHS T32 AI007405NIDDK NIH HHS P30 DK116073NIHNIH HHS AI143261Training Program in Immunology AI074005
6 · The paper itself

Abstract

Persistent antigen exposure during chronic viral infection and tumor development drives CD8 T cells into an exhausted, hypofunctional state. Understanding the molecular pathways that enforce T-cell exhaustion is critical for improving current immunotherapies. Previously, we have shown the bioactive lipid lysophosphatidic acid (LPA) regulates CD8 T-cell function through LPA receptor 5 (LPAR5) signaling, including demonstrating that Lpar5-/- CD8 T cells exhibit enhanced tumor clearance in murine models of melanoma. Importantly, significantly elevated levels of LPA have been identified in individuals with different cancers and persistent viral infections such as HIV, hepatitis C virus, and hepatitis B virus. To investigate the role of Lpar5 in the differentiation and maintenance of exhausted CD8 T cells, we utilized the lymphocytic choriomeningitis virus (LCMV) infection model. In response to infection with LCMV Clone 13, but not Armstrong, one-quarter of Lpar5-/- animals succumbed to infection, and this was accompanied by an increased frequency of LCMV-specific Lpar5-/- CD8 T cells maintained in a less terminally exhausted state. Using P14 transgenic mice, we demonstrate that Lpar5 acts in a cell-intrinsic and temporal manner to regulate CD8 T-cell accumulation and exhaustion programming during Clone 13 infection. The enhanced accumulation of Lpar5-/- P14 cells during the acute phase of Clone 13 infection appears to be regulated by Lpar5-mediated changes in T-cell survival and not through trafficking or proliferation. RNA sequencing analyses and surface phenotyping show that Lpar5 likely regulates CD8 T-cell exhaustion through modulation of NK receptor expression, including the CD94/NKG2A inhibitory axis.

Indexed as

CD8-Positive T-LymphocytesKiller Cells, NaturalLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusReceptors, Lysophosphatidic AcidAnimalsCell SurvivalMiceMice, Inbred C57BLMice, KnockoutReceptors, Lysophosphatidic AcidCD8 T cellsLCMVLPALPAR5T-cell exhaustion

Identifiers

PMID40882982
PMCPMC12646061

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.